J. Engelman

Oncology · 2006–2017

A researcher in the Science corpus: 33 papers; trusts 17 researchers and is trusted by 15 researchers here, as inferred from the citation graph.

Subfields

Whom J. Engelman trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Lewis C. Cantley
  2. William Pao
  3. H. Horlings
  4. Yardena Samuels
  5. B. Manning
  6. K. Inoki
  7. P. Jänne
  8. Dos D. Sarbassov
  9. Y. Yarden
  10. K. Okkenhaug

Who trusts J. Engelman overall

  1. Carlos L. Arteaga
  2. M. V. Vander Heiden
  3. T. Yuan
  4. R. Roskoski
  5. Ingrid A. Mayer
  6. F. Janku
  7. A. De Luca
  8. Lewis C. Cantley
  9. D. Fruman
  10. B. Chan

Papers from J. Engelman's perspective

Ordered by how strongly the researchers J. Engelman trusts endorse each paper. Same corpus, a different order for every researcher.

  1. High Frequency of Mutations of the PIK3CA Gene in Human Cancers (Science)
  2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
  3. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  4. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
  5. Akt regulates growth by directly phosphorylating Tsc2 (Nature Cell Biology)
  6. Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ)
  7. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. (Proceedings of the National Academy of Sciences of the United States of America)
  8. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling (Nature Cell Biology)
  9. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (PLoS Medicine)
  10. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways (Nature Medicine)

Their papers